This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverberg, S. J. Articles by Bilezikian, J. P. Search for Related Content PubMed PubMed Citation Articles by Silverberg, S. J. Articles by Bilezikian, J. P.

Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1–84) in Primary Hyperparathyroidism

Departments of Medicine (S.J.S., I.B., J.P.B.), Pharmacology (J.P.B.), and Surgery (P.L.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; and Scantibodies Laboratory (P.G., T.L.C.), Santee, California 92071

Address all correspondence and requests for reprints to: Shonni J. Silverberg, M.D., Department of Medicine, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032. E-mail: sjs5{at}columbia.edu.

The reliable diagnosis of primary hyperparathyroidism depends on the measurement of PTH. The PTH assays in widespread use measure not only the hormone but also hormone fragments, thus limiting the clinical utility of the assays. A new immunoradiometric assay (IRMA) using an antigenic determinant at the extreme amino-terminal of the PTH molecule detects only full-length PTH (1–84). We compared three PTH assays and determined the presence of PTH (1–84) and PTH fragments in serum and parathyroid adenomas of patients with primary hyperparathyroidism. We studied 56 patients with primary hyperparathyroidism. PTH levels were increased in 63% using the midmolecule RIA; in 73% in the "intact" IRMA; and in 96% in the PTH (1–84)-IRMA. The PTH (1–84)-IRMA correlated with the other assays (midmolecule RIA R = +0.736; P < 0.0001; "intact"-IRMA R = +0.951; P < 0.0001) and indices of disease activity (serum calcium R = +0.511, P < 0.0001; alkaline phosphatase R = +0.489, P = 0.001; and radius bone density R = -0.366, P < 0.01). In 21 consecutive patients undergoing parathyroidectomy, 18 had parathyroid adenomas. Intact PTH was higher than PTH (1–84)-IRMA in both serum and glandular homogenates from these patients. Similar proportions of PTH (1–84) and hormone fragments were found in both adenomas [66 ± 3% of "intact" PTH-reflected PTH (1–84) and sera (73 ± 2% of "intact" PTH reflected PTH (1–84)]. We conclude that the PTH (1–84)-IRMA offers improved diagnostic sensitivity in patients with primary hyperparathyroidism than other currently available assays. This study also provides evidence that both PTH (1–84) and PTH fragments are produced in parathyroid adenomas and that peripheral metabolism of hormone and fragment does not alter the proportion of bioactive hormone.

This work was supported in part by National Institutes of Health Grant NIDDK 32333.

Abbreviation: IRMA, Immunoradiometric assay.

This article has been cited by other articles:

				R. Eastell, A. Arnold, M. L. Brandi, E. M. Brown, P. D'Amour, D. A. Hanley, D. S. Rao, M. R. Rubin, D. Goltzman, S. J. Silverberg, et al. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 340 - 350. [Abstract] [Full Text] [PDF]

				F. W. Lafferty, C. R. Hamlin, K. R. Corrado, A. Arnold, and J. M. Shuck Primary Hyperparathyroidism with a Low-Normal, Atypical Serum Parathyroid Hormone as Shown by Discordant Immunoassay Curves J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3826 - 3829. [Abstract] [Full Text] [PDF]

				P. Boudou, F. Ibrahim, C. Cormier, E. Sarfati, and J.-C. Souberbielle Unexpected Serum Parathyroid Hormone Profiles in Some Patients with Primary Hyperparathyroidism Clin. Chem., April 1, 2006; 52(4): 757 - 760. [Abstract] [Full Text] [PDF]

				P. Boudou, F. Ibrahim, C. Cormier, A. Chabas, E. Sarfati, and J.-C. Souberbielle Third- or Second-Generation Parathyroid Hormone Assays: A Remaining Debate in the Diagnosis of Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6370 - 6372. [Abstract] [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				J.-C. Souberbielle, V. Fayol, C. Sault, E. Lawson-Body, A. Kahan, and C. Cormier Assay-Specific Decision Limits for Two New Automated Parathyroid Hormone and 25-Hydroxyvitamin D Assays Clin. Chem., February 1, 2005; 51(2): 395 - 400. [Abstract] [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]

				S. J. Silverberg and J. P. Bilezikian "Incipient" Primary Hyperparathyroidism: A "Forme Fruste" of an Old Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5348 - 5352. [Abstract] [Full Text] [PDF]